CD8A and neoplasm: In line with this, engineered MSCs were recently designed to deliver IL-2 to tumor-infiltrating CD8+ T-cells and were thereby able to expand this immune population, inducing systemic anti-tumor immunity and alleviating ICB resistance (38).